{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B+Cell+Non-Hodgkin%27s+Lymphoma", "query": { "condition": "B Cell Non-Hodgkin's Lymphoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1927, "total_pages": 193, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B+Cell+Non-Hodgkin%27s+Lymphoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-25T00:18:16.577Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01429025", "title": "Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory/Relapsed Indolent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bendamustine", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2012-05", "completion_date": "2019-07-01", "has_results": false, "last_update_posted_date": "2019-10-08", "last_synced_at": "2026-07-25T00:18:16.577Z", "location_count": 17, "location_summary": "Clive, Iowa • Des Moines, Iowa • Sioux City, Iowa + 3 more", "locations": [ { "city": "Clive", "state": "Iowa" }, { "city": "Clive", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01429025" }, { "nct_id": "NCT06625203", "title": "A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diffuse Large B Cell Lymphoma", "Solid Tumor Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "OWKIN", "sponsor_class": "UNKNOWN", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7000, "start_date": "2023-05-08", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-07-25T00:18:16.577Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625203" }, { "nct_id": "NCT00274924", "title": "Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 100, "start_date": "2006-09-26", "completion_date": "2019-03", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-07-25T00:18:16.577Z", "location_count": 104, "location_summary": "Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Aurora", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00274924" }, { "nct_id": "NCT03630159", "title": "Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Tisagenlecleucel", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-10-09", "completion_date": "2021-07-20", "has_results": false, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-07-25T00:18:16.577Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03630159" }, { "nct_id": "NCT01676805", "title": "Tissue Collection for Studies of Lymph Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hodgkin Disease", "Lymphoma, Non-Hodgkin", "Multiple Myeloma", "Lymphomatoid Granulomatosis", "Leukemia-Lymphoma, Adult T-Cell" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1295, "start_date": "2012-09-21", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-07-25T00:18:16.577Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01676805" }, { "nct_id": "NCT01874288", "title": "A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "DI-Leu16-IL2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alopexx Oncology, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2013-11-25", "completion_date": "2016-11-16", "has_results": true, "last_update_posted_date": "2020-11-24", "last_synced_at": "2026-07-25T00:18:16.577Z", "location_count": 5, "location_summary": "Duarte, California • Fullerton, California • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01874288" }, { "nct_id": "NCT00121186", "title": "S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2005-07", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2012-04-03", "last_synced_at": "2026-07-25T00:18:16.577Z", "location_count": 33, "location_summary": "Maywood, Illinois • Beech Grove, Indiana • Richmond, Indiana + 20 more", "locations": [ { "city": "Maywood", "state": "Illinois" }, { "city": "Beech Grove", "state": "Indiana" }, { "city": "Richmond", "state": "Indiana" }, { "city": "Chanute", "state": "Kansas" }, { "city": "Dodge City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00121186" }, { "nct_id": "NCT02727803", "title": "Personalized NK Cell Therapy in CBT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Biphenotypic Leukemia", "Acute Lymphoblastic Leukemia", "Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia With Myelodysplasia-Related Changes", "Acute Myeloid Leukemia With Variant MLL Translocations", "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Chemotherapy-Related Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "ISS Stage II Plasma Cell Myeloma", "ISS Stage III Plasma Cell Myeloma", "Myelodysplastic Syndrome", "Myelodysplastic Syndrome With Excess Blasts", "Myelodysplastic Syndrome With Gene Mutation", "Myelodysplastic/Myeloproliferative Neoplasm", "Previously Treated Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Hodgkin Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Adult Acute Lymphoblastic Leukemia", "Secondary Acute Myeloid Leukemia", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "Allogeneic Natural Killer Cell Line NK-92", "type": "BIOLOGICAL" }, { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "15 Years to 80 Years" }, "enrollment_count": 100, "start_date": "2016-05-19", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-07-25T00:18:16.577Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02727803" }, { "nct_id": "NCT00002880", "title": "Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Etoposide phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 53, "start_date": "1996-11", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2016-06-28", "last_synced_at": "2026-07-25T00:18:16.577Z", "location_count": 4, "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Paterson, New Jersey + 1 more", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Paterson", "state": "New Jersey" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002880" }, { "nct_id": "NCT00499239", "title": "A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "GS-9219", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2007-07", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2014-02-04", "last_synced_at": "2026-07-25T00:18:16.577Z", "location_count": 5, "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499239" } ] }